Qingyu Wang

1.1k total citations
48 papers, 264 citations indexed

About

Qingyu Wang is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Qingyu Wang has authored 48 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Qingyu Wang's work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Qingyu Wang is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Qingyu Wang collaborates with scholars based in China, United States and Hong Kong. Qingyu Wang's co-authors include Xin Gen Lei, Hua Hao, Hao Zhang, Silu Chen, Fazheng Ren, Jiaqiang Huang, Dmytro Trukhin, Mei Zhang, Tiantian Wang and Hryhoriy Adamchuk and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Qingyu Wang

39 papers receiving 261 citations

Peers

Countries citing papers authored by Qingyu Wang

Since Specialization

Citations

This map shows the geographic impact of Qingyu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingyu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingyu Wang more than expected).

Fields of papers citing papers by Qingyu Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingyu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingyu Wang. The network helps show where Qingyu Wang may publish in the future.

Co-authorship network of co-authors of Qingyu Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Qingyu Wang. A scholar is included among the top collaborators of Qingyu Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingyu Wang. Qingyu Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Facilitators and barriers affecting the implementation of diabetes prevention programs in primary care settings: A qualitative meta-synthesis from a multi-stakeholder perspective 2025 ·International Journal of Nursing Studies ·Jiali Chen, (unknown), (unknown), Qingyu Wang, (unknown), Hung‐Yuan Cheng	0
2	Akkermansia muciniphila inhibits jejunal lipid absorption and regulates jejunal core bacteria 2025 ·Microbiological Research ·(unknown), Xincheng Zhou, Wenmei Su, Qingyu Wang, (unknown), (unknown), (unknown), Cunchuan Wang, Chris K.C. Wong, Tiemin Liu, Shiqi Jia	1
3	An updated Pig Haplotype Reference Panel (PHARP 4.0) comprising 13,298 haplotypes 2025 ·Communications Biology ·Qingyu Wang, Zhenyang Zhang, (unknown), (unknown), Jiabao Sun, (unknown), (unknown), (unknown), Zhong Xu, Kejun Wang, Wei Zhao, Hao Sun, (unknown), Qishan Wang, Yuchun Pan, (unknown), (unknown)	0
4	High energy density in polymer nanocomposites with electrophilic disordered nanostructures at extreme temperature 2025 ·Composites Part B Engineering ·(unknown), Congzhen Xie, Daoming Zhang, Zhong An, Jiangang Zhou, Qingyu Wang, (unknown), Yongxia Han, Kui Shen, Rui Wang	1
5	The Regeneration of Intestinal Stem Cells Is Driven by miR-29-Induced Metabolic Reprogramming 2024 ·Engineering ·Yingying Lin, Yao Lu, Yuqi Wang, Cong Lv, Juan Chen, (unknown), (unknown), (unknown), Lining Chen, Ziyu Huang, Yanling Hao, Qingyu Wang, Qingfeng Luo, Jingyu Yan, Yixuan Li, Wei Zhang, Min Du, (unknown), Fazheng Ren, Huiyuan Guo	3
6	First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study. 2024 ·Journal of Clinical Oncology ·Feng Wang, (unknown), Junjie Peng, Xinjun Liang, Ying Cheng, Yanhong Deng, (unknown), Mingjun Zhang, Jingdong Zhang, Wei Wang, Bangwei Cao, Yongdong Jin, Meili Sun, Yuan Lin, (unknown), Zhen Li, Yang Liu, Jing Li, Qingyu Wang, Rui‐Hua Xu, (unknown)	2
7	Effects of Yersinia pseudotuberculosis outer membrane vesicles on Pseudomonas aeruginosa antigens immune response 2024 ·PLoS ONE ·(unknown), (unknown), Mingru Zhang, Zhe Zhang, Nan Li, Yuqin Fu, Zhe Sun, Tiancheng Lu, Siyuan Li, (unknown), Qingyu Wang, Chunhui Sun, Xiuran Wang	2
8	HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study. 2024 ·Journal of Clinical Oncology ·Jin Li, Yong Gao, Ning Li, Meng Qiu, Yanqiao Zhang, (unknown), (unknown), Wei Li, Yuntao Ma, Xiaoming Hou, Guoping Sun, (unknown), Jingran Wang, Jianwei Lu, Diansheng Zhong, (unknown), (unknown), Qingyu Wang, Jun Zhu, (unknown)	0
9	Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study. 2024 ·Journal of Clinical Oncology ·Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, (unknown), (unknown), Qingyu Wang, Jun Zhu, (unknown)	0
10	Recent advancements in polymeric heart valves: From basic research to clinical trials 2024 ·Materials Today Bio ·(unknown), (unknown), Qingyu Wang, Deling Kong, Zhihong Wang, (unknown)	9
11	Role of cancer-associated fibroblasts in colorectal cancer and their potential as therapeutic targets 2023 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), Qingyu Wang, Hua Hao	8
12	HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial 2023 ·Investigational New Drugs ·Xiaoxue Zhu, Yanhua Ding, Qian Wang, (unknown), Liang Zhou, Qingyu Wang	4
13	Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study 2023 ·Frontiers in Immunology ·Jusheng An, Xiu-Min Li, Jing Wang, Lijing Zhu, Ruifang An, (unknown), Yi Huang, Ke Wang, Guiling Li, Chunyan Wang, (unknown), (unknown), (unknown), Jing Li, Qingyu Wang, Junwu Zhu, Lingying Wu	10
14	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial 2022 ·British Journal of Cancer ·Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, (unknown), Peiguo Cao, (unknown), Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Han Lin, Qingyu Wang, Junwu Zhu, (unknown)	15
15	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma 2022 ·Liver Cancer ·(unknown), Guoliang Shao, (unknown), (unknown), Xu Zhu, Weijia Fang, (unknown), Yuxian Bai, Jianbing Wu, Lianxin Liu, (unknown), Jingdong Zhang, Zhen Li, Ling Zhang, Tao Yin, Jincai Wu, (unknown), Qingyu Wang, Junwu Zhu, (unknown), (unknown)	7
16	Pediatric bronchogenic cysts in the head and neck region: A study of 10 surgical cases and a review of the literature 2022 ·Frontiers in Pediatrics ·Wei Chen, (unknown), Qingyu Wang, Hongming Xu, (unknown), Xiaoyan Li	3
17	HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects 2022 ·BioDrugs ·Jingjing Yang, (unknown), (unknown), Qian Zhang, (unknown), (unknown), Qingyu Wang, Jun Zhu, Fanfan Li, Wei Hu	5
18	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial 2021 ·BioDrugs ·Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang, (unknown)	28
19	BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway 2020 ·International Immunopharmacology ·Lan Lin, (unknown), Lin Wang, Fen Xu, Yuanqiao He, Qingyu Wang, Chunlei Yuan, Jing Xu, (unknown), Hua Hao	11
20	A clinical study on the therapeutic effect of rituximab in combination with autologous peripheral blood stem cell transplantation in treatment of CD20+ B cellulous non-Hodgkin lymphoma 2013 ·SHILAP Revista de lepidopterología ·Yongsheng Chen, Peiyan Kong, Dongfeng Zeng, Jieping Li, Xinghua Chen, Xi Zhang, Jiali Li, (unknown), Cheng Zhang, Qingyu Wang, (unknown), Yuanyuan He	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact